Report on the 1999 financial year

Report on the 1999 financial year (Göteborg, 9 February 2000) The Nobel Biocare Group * Operating income increased by 91% compared with operating income before non-recurring items in 1998 and amounted to SEK 232.6 million (121.5). * Sales increased by 33% to total SEK 1,738.1 million (1,309.7). * Dental Implant sales improved by 31% to total SEK 1,528.4 million (1,170.2). * Sales within Procera® increased by 50% and totalled SEK 209.7 million (139.5). * Earnings per share excluding goodwill amortization and non-recurring items increased by 87% to SEK 8.39 (4.49). * The Board of Directors proposes that the dividend should be increased to SEK 2.00 per share (1.70). SEK M 1999 1998 Change Net turnover 1 738.1 1 309.7 +32.7% of which Dental Implants 1 528.4 1 170.2 +30.6% ® of which Procera 209.7 139.5 +50.3% Operating income excluding non-recurring 232.6 121.5 +91.4% items Non-recurring items - -47.7 Operating income 232.6 73.8 +215.2% Income after net financial items 197.9 64.7 +205.9% Earnings per share, SEK 6.21 1.88 +230.3% Earnings per share excluding goodwill amortization and non-recurring items, SEK 8.39 4.49 +86.9% 1998 includes four months of Steri-Oss' operations ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/2000/02/09/20000209BIT00540/bit0001.doc http://www.bit.se/bitonline/2000/02/09/20000209BIT00540/bit0002.pdf

About Us

Nobel Biocare is the world leader in innovative esthetic dental solutions with the brands Brånemark System® ,Replace® Select and Procera®.Nobel Biocare has around 1,300 employees and, in 2001 net sales totaled SEK 2 663 million. The company's headquarters are located in Gothenburg, Sweden. Nobel Biocare has its own sales organizations in 27 countries. The shares of the parent company Nobel Biocare Holding AG are listed on both the SWX Swiss Exchange and the Stockholm Stock Exchange.

Subscribe